Hoffmann-La Roche, founded in 1896 in Basel, Switzerland, grew from a small pharmaceutical company into a global healthcare leader. With pioneering innovations in vitamins, benzodiazepines, cancer therapies, and diagnostics, Roche shaped modern medicine through strategic acquisitions and research breakthroughs.
F. Hoffmann-La Roche & Co. is founded in Basel, Switzerland, by Fritz Hoffmann-La Roche, initially focusing on the production of pharmaceutical specialties. #pharmaceutical #swiss
Roche launches Airol, a bismuth compound used for wound treatment, marking its first major commercial product. #pharmaceutical #history
Roche establishes its first international subsidiary in Grenzach, Germany, expanding its reach beyond Switzerland. #expansion
Roche opens its first dedicated research laboratory in Basel, laying the foundation for its future drug discovery efforts. #research #pharmaceutical
Roche begins research into synthetic vitamins, eventually becoming a world leader in vitamin production and fortification. #vitamins #innovation
Founder Fritz Hoffmann-La Roche dies, leading to a transition in leadership and eventual restructuring of the company's ownership. #leadership
Roche establishes a subsidiary in Welwyn Garden City, UK, beginning its presence in the British pharmaceutical market. #expansion #uk
Roche launches large-scale production of synthetic vitamin C (ascorbic acid), revolutionizing nutrition and supplement markets. #vitamins #pharmaceutical
Roche opens its first pharmaceutical manufacturing facility in the United States in Nutley, New Jersey. #expansion #usa
After World War II, Roche expands into antibiotics, particularly penicillin and streptomycin, to meet growing demand. #antibiotics #postwar
Roche introduces Librium (chlordiazepoxide), the first benzodiazepine, revolutionizing the treatment of anxiety and insomnia. #pharmaceutical #psychiatry
Roche launches Valium (diazepam), which becomes the best-selling pharmaceutical in the world for a decade, transforming psychiatric medicine. #benzodiazepine #blockbuster
Roche introduces Bactrim (co-trimoxazole), a combination antibiotic that becomes widely used for infections. #antibiotic
Roche begins development of Roferon-A (interferon alfa-2a), a pioneering biologic for cancer treatment. #biotech #cancer
Roche acquires full control of its German subsidiary, Deutsche Hoffmann-La Roche AG, consolidating its European operations. #acquisition
Roche launches Accutane (isotretinoin) for severe acne, which becomes a blockbuster despite side effect controversies. #dermatology #pharmaceutical
Roche introduces Haldol (haloperidol) for psychiatric conditions, expanding its psychopharmacology portfolio. #psychiatry #pharmaceutical
Roche acquires Molecular Genetics Inc., a US biotech firm, signaling entry into genetic engineering and biotechnology. #biotech #acquisition
Roche acquires a majority stake in Genentech, the leading US biotechnology company, for $2.1 billion, marking a major biotech push. #biotech #acquisition
Roche launches Rocephin (ceftriaxone), a broad-spectrum injectable antibiotic that becomes a major revenue driver. #antibiotic #pharmaceutical
Roche acquires Syntex Corp., a US pharmaceutical firm, for $5.3 billion, gaining rights to drugs like Naprosyn and expanding its sales force. #acquisition #pharmaceutical
Roche launches Toradol (ketorolac), a nonsteroidal anti-inflammatory drug (NSAID) for pain management. #pain #pharmaceutical
Roche celebrates its 100th anniversary as a global pharmaceutical leader with events and community initiatives. #anniversary
Roche launches Tamiflu (oseltamivir), an antiviral drug for influenza, which later becomes a key stockpile for pandemic preparedness. #antiviral #pandemic
Roche launches Xenical (orlistat), a weight-loss drug that becomes a blockbuster despite side effects. #obesity #pharmaceutical
Roche acquires the remaining shares of its Japanese subsidiary Nippon Roche K.K., strengthening its presence in Asia. #acquisition #japan
Roche launches Pegasys (peginterferon alfa-2a) for hepatitis C, becoming a standard of care in combination therapy. #hepatitis #pharmaceutical
Roche acquires rights to Igen International's technology for diagnostic applications, boosting its diagnostics division. #diagnostics #acquisition
Roche launches Avastin (bevacizumab), a monoclonal antibody for colorectal cancer, the first approved anti-angiogenic therapy. #cancer #biotech
Roche launches Tarceva (erlotinib) for lung cancer, an EGFR inhibitor that extends survival. #cancer #targetedtherapy
Roche launches Herceptin (trastuzumab) for HER2-positive breast cancer, a landmark targeted therapy. #cancer #biotech
Roche acquires full ownership of Genentech for $46.8 billion, one of the largest biotech acquisitions, solidifying its oncology leadership. #biotech #acquisition
Roche acquires InterMune for $8.3 billion, gaining rights to Esbriet (pirfenidone) for idiopathic pulmonary fibrosis. #acquisition #pharmaceutical
Roche launches Gazyva (obinutuzumab) for chronic lymphocytic leukemia, a next-generation anti-CD20 antibody. #cancer #biotech
Roche launches Ocrevus (ocrelizumab) for multiple sclerosis, the first therapy approved for both relapsing and primary progressive forms. #neurology #multiple_sclerosis
Roche acquires a majority stake in Foundation Medicine, a leader in genomic profiling and precision oncology diagnostics. #diagnostics #genomics
Roche launches Hemlibra (emicizumab) for hemophilia A, a bispecific antibody that reduces bleeding episodes. #hemophilia #biotech
Roche launches a high-volume PCR test for COVID-19, followed by serology tests, playing a crucial role in pandemic response. #covid19 #diagnostics
Roche completes acquisition of Spark Therapeutics for $4.8 billion, gaining Luxturna gene therapy and expanding into gene medicine. #genetherapy #acquisition
Roche launches Vabysmo (faricimab) for wet age-related macular degeneration and diabetic macular edema, a bispecific antibody. #ophthalmology #biotech
Severin Schwan steps down as CEO after 14 years, replaced by Thomas Schinecker, marking a new era in digital health and diagnostics. #leadership #ceo
